Senzime has decided to apply for listing on the Nasdaq Stockholm’s Main Market in 2021

Senzime has decided to apply for listing on the Nasdaq Stockholm’s Main Market in 2021

The company has made the decision as a step in its continued expansion and in line with its commercial strategy. The company is in a strong growth and expansion phase with its own sales force in both the US and Germany, combined with having licensors and distributors on strategic focus markets in Europe, South Korea and Japan. A listing on Nasdaq Stockholm’s Main Market is seen as a logical next step in the company’s development. 

Pia Renaudin, CEO of Senzime, said: “A listing on the Nasdaq Stockholm Main Market can contribute to increased interest from a broader investor base and at the same time increase the visibility and exposure of Senzime. It also serves as a quality stamp on the work that has already been carried out internally within the company. We look forward to offer more investors the opportunity to follow us on our exciting global journey.”

Senzime was founded in Uppsala in 1999. The company’s shares were listed on Aktietorget (currently Spotlight Stock Market) in 2008 and in 2017 on Nasdaq Stockholm First North Growth Market.

For further information, please contact: 

Pia Renaudin, CEO of Senzime AB                                                             

Tel: +46 (0)70-813 34 17, email:

About Senzime

Senzime develops and markets CE- and FDA cleared patient monitoring systems driven by unique algorithms and sensors to closely monitor patients under anesthesia. TetraGraph is a system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow guidelines and drug recommendations, TetraGraph can contribute to shorten hospital stays and lower healthcare costs. The vision is a world without anesthesia related complications, where everyone wakes up safely after surgery. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 15 billion. The company's shares are listed on Nasdaq
First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, is Certified Adviser for Senzime.

Contact us

Want to know more?

How can Senzime’s innovative patient monitoring solutions help to eliminate in-hospital complications?
Contact us today.